Author
McLean & Friedman named to associate provost role
Dec. 16, 2022—Two veteran faculty members, highly regarded for their administrative leadership within their respective departments and their deep commitment to research and student development, have been appointed associate provosts at Vanderbilt University, announced Provost and Vice Chancellor for Academic Affairs C. Cybele Raver. John McLean, Stevenson Professor of Chemistry and chair of the Department of Chemistry,...
James Crowe awarded “TIME” Best Inventions of 2022
Dec. 5, 2022—Dr. James Crowe Jr., director of the Vanderbilt Vaccine Center at Vanderbilt University Medical Center, led the team that discovered a monoclonal antibody combination that protects against COVID-19. Optimized and developed by AstraZeneca, the monoclonal antibody combination called Evusheld is the first treatment to protect adults and children 12 years and older who have compromised immune...
Lindsley named 2022 fellow of American Society for Pharmacology and Experimental Therapeutics
Nov. 30, 2022—Craig W. Lindsley, University Distinguished Professor of Pharmacology, Biochemistry and Chemistry, who holds the William K. Warren, Jr. Chair in Medicine, was recently announced as a 2022 fellow of the American Society for Pharmacology and Experimental Therapeutics for his demonstrated excellence and contributions to pharmacology and to the ASPET organization.
Vanderbilt-Ancora partnership advances research for rare form of epileps
Nov. 1, 2022—Vanderbilt researchers’ partnership with Ancora Innovation LLC, a Deerfield Management company that supports Vanderbilt University’s innovative life science research, has added an effort to develop therapeutics for a rare form of epilepsy. This is the fourth drug discovery and development program supported through the Ancora-Vanderbilt collaboration.
ACS journal dedicates of 35-year anniversary issue to founding editor Larry Marnett
Oct. 18, 2022—In this issue of the 35th volume of Chemical Research in Toxicology (CRT), we share a special collection of science that celebrates the tremendous advances in this period at the intersection of chemistry and toxicology. Throughout the year, every issue of the Journal has borne a 35-year anniversary symbol to mark this milestone. This issue...
Vanderbilt’s Crowe receives the Building the Foundation Award from Research!America
Oct. 7, 2022—James Crowe Jr., MD, director of the Vanderbilt Vaccine Center at Vanderbilt University Medical Center, has received the Building the Foundation Award from Research!America, a national biomedical research advocacy organization, for his team’s role in developing human monoclonal antibodies and vaccine candidates against COVID-19. The award, which was announced Oct. 6, recognizes individuals whose basic research...
Erik Skaar et al land grant to build top-line biosafety facility
Sep. 30, 2022—Vanderbilt University Medical Center has been awarded a nearly $8 million grant from the National Institutes of Health to construct a state-of-the-art BioSafety Level 3 (BSL3) facility for research involving the COVID-19 virus, anthrax and other dangerous microorganisms. VUMC currently has two BSL3 labs, but they are small, outdated and can accommodate only a few investigators....
Colon cancer researchers awarded NCI grant for study of early lesions
Sep. 29, 2022—Vanderbilt University Medical Center has received a five-year, $5 million grant from the National Cancer Institute to study precancerous lesions and early cancers in the colon, with the goal of developing new ways to prevent colorectal cancer, the nation’s second leading cancer killer. Ken Lau, PhD, left, Robert Coffey, MD, Martha Shrubsole, PhD, and colleagues are...
John Wilson to use $3 million grant to develop technology to help cancer patients better fight disease
Sep. 7, 2022—John Wilson, associate professor of chemical and biomolecular engineering at Vanderbilt University, has received a $3 million grant from the National Cancer Institute to develop technology that seeks to boost a person’s immune system to better fight cancer. Wilson is the Principal Investigator of the five-year grant. He specializes in the study of cancer immunotherapy...
COVID antibody research conducted at VUMC lands national award
Aug. 25, 2022—A long-acting antibody combination discovered at Vanderbilt University Medical Center that protects against COVID-19 in high-risk individuals, and which was optimized and developed by the global pharmaceutical company AstraZeneca, has received a gold medal in the 2022 R&D 100 awards program announced Aug. 22 by R&D World Magazine. Now in its 60th year, the R&D...